Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 4,225 matching trials from the local directory fallback.

Filters: Intervention: placebo Clear all

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: KarX-EC, KarXT, KarXT + KarX-EC Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 25 more

Conditions: Cancer Treatment, Neuropathic Pain
Interventions: Green Tea Leaf Extract Decaffeinated, Placebo Control; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypothyroidism Primary
Interventions: Levothyroxine Sodium (LT4) Tablets, Liothyronine (L-T3), Liothyronine (LT3) placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol Use Disorder
Interventions: Methylphenidate Pill, Placebo Pill; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Oral Health Related Quality of Life (OHRQoL)
Interventions: Botanical A, Botanical B, Vehicle (Placebo solution); Dietary Supplement
Lead sponsor: Access Business Group; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Menopause Hot Flashes
Interventions: Fezolinetant, Placebo; Drug
Lead sponsor: Rebecca Thurston; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Down Syndrome (DS)
Interventions: MIB-626, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Intermittent Claudication, Peripheral Arterial Disease, Stenosis
Interventions: FGF-1, Placebo; Drug
Lead sponsor: Venturis Therapeutics, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Excision Margin, Mohs Micrographic Surgery
Interventions: Hydrogel of placebo, Timolol 0.5% Ophthalmic Solution; Other · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Sacramento, California

Conditions: HIV -1 Infection, Methamphetamine Use
Interventions: Oral Methamphetamine, Placebo oral capsule; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Carbon Monoxide Encephalopathy, Carbon Monoxide Intoxication, Carbon Monoxide Poisoning, Carbon Monoxide-induced Parkinsonism
Interventions: Dexamethasone, saline placebo; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cornelia de Lange Syndrome
Interventions: N-acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anterior Uveitis, CMV Infection, Cytomegalovirus (CMV), Infectious Uveitis
Interventions: Ganciclovir (GCV), Placebo, Valganciclovir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions: Aspirin, Clopidogrel, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes (DM)
Interventions: Glucagon, Saline (placebo); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Fatigue
Interventions: Active Fatigue Product 1A, Active Fatigue Product 1B, Placebo Fatigue Control 1A, Placebo Fatigue Control 1B; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 40 Years to 105 Years
Enrollment: 1,320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Endocrine System Diseases, Genital Diseases, Male, Gonadal Disorders, Hypogonadism, Injuries, Spinal Cord, Nervous System Diseases, Spinal Cord Compression, Spinal Cord Contusion, Spinal Cord Diseases, Spinal Cord Injuries, Spinal Cord Injury, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries
Interventions: finasteride, placebo injection, placebo pill, testosterone cypionate; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 4
States / cities: Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more

Conditions: Dental Caries
Interventions: Placebo, Povidone Iodine 5% Soln,Top,Kit, Probiotics; Drug · Dietary Supplement
Lead sponsor: Jeffrey A. Banas; Other
Eligibility: 1 Year to 3 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cannabis Use
Interventions: Beta-Myrcene, Placebo, THC; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism, Childhood Apraxia of Speech, Verbal Apraxia
Interventions: L-carnitine, Omega-DEK, Placebo; Drug
Lead sponsor: Claudia R. Morris; Other
Eligibility: 36 Months to 6 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Chronic Lower Back Pain, Lower Back Pain, Obesity (BMI>30), glp1 Agonist
Interventions: Placebo (administered by PDS290 pen-injector), Semaglutide (administered by PDS290 pen-injector); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • St Louis, Missouri

Conditions: ACL Reconstruction (ACLR) With a Bone-patellar Tendon-bone (BPTB) Autograft
Interventions: Pacira Iovera Cryoneurolysis device, Placebo/Sham device; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 45 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Inflammation, Obesity, Rheumatoid Arthritis
Interventions: Disulfiram (DSF), Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain

T4/T3 Therapy in Hypothyroidism

Methylphenidate and Response to Alcohol Cues

Vascular Effects of SGLT2i in Non-diabetic CKD

New Functional Ingredient for Oral Care

Fezolinetant and Vascular Health and Brain Health

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing

Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

A Clinical Trial of Antiplatelets in Psoriasis

Studies of Insulin and Glucagon Action in the Liver

Radicle Energy™ DNB: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

Povidone Iodine for Caries Prevention

Behavioral Pharmacology of THC and Beta-Myrcene

Role of Omega-DEK in Childhood Apraxia of Speech

Semaglutide for Low Back Pain

Cryoneurolysis in Anterior Cruciate Ligament Reconstruction (ACLR)

Disulfiram in Rheumatoid Arthritis